These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24292607)

  • 1. A Multicenter Phase I/II Study of the BCNU Implant (Gliadel
    Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi JI; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M
    Neurol Med Chir (Tokyo); 2013 Nov; ():. PubMed ID: 24292607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
    Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi J; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M;
    Neurol Med Chir (Tokyo); 2014; 54(4):290-301. PubMed ID: 24739422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
    Sai K; Zhong MG; Wang J; Chen YS; Mou YG; Ke C; Zhang XH; Yang QY; Lin FH; Guo CC; Chen ZH; Zeng J; Lv YC; Li X; Gao WC; Chen ZP
    J Neurol Sci; 2014 Aug; 343(1-2):60-5. PubMed ID: 24874252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
    Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
    Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.
    Kleinberg L
    Core Evid; 2012; 7():115-30. PubMed ID: 23118709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk management in the treatment of malignant gliomas with BCNU wafer implants.
    Giese A; Bock HC; Kantelhardt SR; Rohde V
    Cent Eur Neurosurg; 2010 Nov; 71(4):199-206. PubMed ID: 20063259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.
    Bota DA; Desjardins A; Quinn JA; Affronti ML; Friedman HS
    Ther Clin Risk Manag; 2007 Oct; 3(5):707-15. PubMed ID: 18472995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
    McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
    J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
    Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
    Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
    Sabel M; Giese A
    Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
    Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
    J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
    Westphal M; Ram Z; Riddle V; Hilt D; Bortey E;
    Acta Neurochir (Wien); 2006 Mar; 148(3):269-75; discussion 275. PubMed ID: 16482400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.
    Kleinberg L
    Patient Prefer Adherence; 2016; 10():2397-2406. PubMed ID: 27920506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
    Fujii Y; Ogiwara T; Kato H; Hanaoka Y; Hardian RF; Goto T; Hongo K; Horiuchi T
    Neurol Med Chir (Tokyo); 2022 Jul; 62(7):328-335. PubMed ID: 35613880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
    Ashby LS; Smith KA; Stea B
    World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors.
    Ene CI; Nerva JD; Morton RP; Barkley AS; Barber JK; Ko AL; Silbergeld DL
    Surg Neurol Int; 2016; 7(Suppl 11):S295-9. PubMed ID: 27217968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
    Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
    Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.